Publikationen

Ganzleben I, He GW, Günther C, Prigge ES, Richter K, Rieker RJ, Mougiakakos D, Neurath MF, Becker C. PGAM5 is a key driver of mitochondrial dysfunction in experimental lung fibrosis. Cell Mol Life Sci. 2019 Dec;76(23):4783-4794. doi: 10.1007/s00018-019-03133-1. Epub 2019 Jun 5.

Kachler K, Holzinger C, Trufa DI, Sirbu H, Finotto S.The role of Foxp3 and Tbet co-expressing Treg cells in lung carcinoma. Oncoimmunology. 2018 Apr 25;7(8):e1456612. doi: 10.1080/2162402X.2018.1456612. eCollection 2018.

Schreiner W, Gavrychenkova S, Dudek W, Rieker RJ, Lettmaier S, Fietkau R, Sirbu H.Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer. J Thorac Dis. 2018 May;10(5):2795-2803. doi: 10.21037/jtd.2018.05.68.

Hecht M, Gaipl US, Fietkau R. Durvalumab improves prognosis of stage III non-small-cell lung cancer after definitive chemoradiotherapy. Strahlenther Onkol. 2018 Mar;194(3):269-271. doi: 10.1007/s00066-017-1253-3. German.

Fietkau R. Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer? Lancet Oncol. 2017 Aug;18(8):994-995. doi: 10.1016/S1470-2045(17)30439-4. Epub 2017 Jun 20. No abstract available.

Temming S, Kocher M, Stoelben E, Hagmeyer L, Chang DH, Frank K, Hekmat K, Wolf J, Baus WW, Semrau R, Baues C, Marnitz S. Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer. Strahlenther Onkol. 2018 Feb;194(2):91-97. doi: 10.1007/s00066-017-1194-x. Epub 2017 Aug 15. Review.